<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571008</url>
  </required_header>
  <id_info>
    <org_study_id>201909118</org_study_id>
    <nct_id>NCT04571008</nct_id>
  </id_info>
  <brief_title>Effect of NMN Supplementation on Organ System Biology</brief_title>
  <acronym>VAN</acronym>
  <official_title>Effect of Nicotinamide Mononucleotide (NMN) Supplementation on Organ System Biology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this proposal is to determine whether the beneficial effects of NMN on metabolic&#xD;
      function observed in rodents applies to people.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is looking at the effect of the dietary supplement &quot;Nicotinamide mononucleotide&quot;&#xD;
      (NMN) on key cardiovascular and metabolic functions, specifically those that are important&#xD;
      risk factors for diabetes and cardiovascular disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Muscle insulin sensitivity</measure>
    <time_frame>before and after at least 16 weeks of treatment</time_frame>
    <description>The outcome will be assessed during hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopic tracer infusion before and after intervention period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose tolerance</measure>
    <time_frame>before and after at least 16 weeks of treatment</time_frame>
    <description>The outcome will be assessed during modified oral glucose tolerance test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Glucose Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>At least 16 weeks of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NMN supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At least 16 weeks of NMN.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intervention will last at least 16 weeks in the form of two capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Treatment</intervention_name>
    <description>Intervention will last at least 16 weeks in the form of two NMN capsules (total of 300 mg/day).</description>
    <arm_group_label>NMN supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI 25.0-34.9 kg/m²&#xD;
&#xD;
          -  Prediabetes defined as a 2-h oral glucose tolerance test plasma glucose of 140-199&#xD;
             mg/dL with or without a fasting plasma glucose of 100-125 mg/dL, or HbA1C ≥5.7.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are still having menses&#xD;
&#xD;
          -  Persons who take niacin, nicotinamide, or other vitamin B3-related supplementation and&#xD;
             are not willing to discontinue supplementation for 3 weeks before medical screening&#xD;
             and during the entire study period&#xD;
&#xD;
          -  Persons who consume moderate-large amounts of caffeine daily (&gt;2 cups of coffee or 8&#xD;
             oz caffeinated drinks per day) or consume less amounts of caffeine but believe&#xD;
             withdrawal symptoms (e.g. headache) are likely if caffeine is stopped&#xD;
&#xD;
          -  Unstable weight (&gt;3% change during the last 2 months before entering the study)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley Roberts</last_name>
    <phone>314-273-1879</phone>
    <email>nutritionresearch@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sally Torbitzky</last_name>
    <phone>314-362-9950</phone>
    <email>storbitz@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Torbitzky, RN, BSN</last_name>
      <phone>314-362-8529</phone>
      <email>storbitz@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Samuel Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mihoko Yoshino, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

